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Abstract: Thyroid carcinoma (TC) comprises several histotypes with different aggressiveness, from 
well (papillary carcinoma, PTC) to less differentiated forms (poorly differentiated and anaplastic 
thyroid carcinoma, PDTC and ATC, respectively). Previous reports have suggested a functional role 
for cancer-associated fibroblasts (CAFs) or senescent TC cells in the progression of PTC. In this 
study, we investigated the presence of CAFs and senescent cells in proprietary human TCs 
including PTC, PDTC, and ATC. Screening for the driving lesions BRAFV600E and N/H/KRAS 
mutations, and gene fusions was also performed to correlate results with tumor genotype. In 
samples with unidentified drivers, transcriptomic profiles were used to establish a BRAF- or RAS-
like molecular subtype based on a gene signature derived from The Cancer Genome Atlas. By using 
immunohistochemistry, we found co-occurrence of stromal CAFs and senescent TC cells at the 
tumor invasive front, where deposition of collagen (COL1A1) and expression of lysyl oxidase (LOX) 
enzyme were also detected, in association with features of local invasion. Concurrent high 
expression of CAFs and of the senescent TC cells markers, COL1A1 and LOX was confirmed in 
different TC histotypes in proprietary and public gene sets derived from Gene Expression Omnibus 
Cancers 2020, 12, 112 2 of 17 
 
(GEO) repository, and especially in BRAF mutated or BRAF-like tumors. In this study, we show that 
CAFs and senescent TC cells co-occur in various histotypes of BRAF-driven thyroid tumors and 
localize at the tumor invasive front. 
Keywords: Thyroid cancer; CAFs; senescent cells; BRAFV600E; BRAF- and RAS-like signaling 
 
1. Introduction 
The vast majority (98%) of thyroid tumors arise from thyroid follicular epithelial cells and 
comprise various histological types and variants, ranging from well differentiated thyroid 
carcinomas (WDTCs) to poorly differentiated (PDTCs) and undifferentiated (anaplastic, ATCs) 
forms. WDTCs account for most of follicular cell derived TCs (80–90%) and comprise papillary and 
follicular thyroid carcinoma (PTC and FTC, respectively) among which PTC (85%) definitively 
outnumbers FTC (15%). PDTC and ATC are rare tumors that can arise de novo from follicular cells 
or develop from pre-existing PTCs or FTCs [1] according to a model of sequential progression from 
low-grade to high-grade thyroid tumors. 
Although they are annotated as well differentiated forms, PTC and FTC differ in terms of nuclear 
features, growth patterns, and the route for metastases dissemination. PTC displays papillary or 
follicular growth patterns and metastatic spreading preferentially via lymphatic vessels, while FTC 
displays follicular growth pattern and dissemination preferentially via blood vessels [2]. 
In addition to the histopathological classification, studies aimed at the identification of 
molecular events driving TC have recently provided evidence that specific genetic alterations play a 
role in the carcinogenesis of various thyroid tumors [1]. Most of the identified driving lesions involve 
the effectors of MAPK and PI3K-AKT signaling pathways. BRAF mutations (mainly BRAFV600E) as 
well as RET and TRK gene fusions are more frequently detected in PTC, while RAS mutations are 
more frequent in FTC [3]. An exception is represented by the follicular variant of PTC that shares 
histological features with both PTC and FTC and harbors frequent RAS mutations [4]. Gene lesions 
associated with well-differentiated forms, in particular BRAF and RAS mutations, are also frequently 
found in PDTC and ATC in association with additional alterations (such as PI3K, PTEN, TP53 and 
TERT promoter mutations [5]), supporting the model of tumor progression from pre-existing PTC or 
FTC driven by sequential accumulation of multiple genetic abnormalities. 
Along with the major drivers, however, less frequent and/or unconventional genetic alterations 
were identified in TCs, but the molecular effects remain to be clarified. To achieve this aim, a major 
improvement has been made by a remarkable study from The Cancer Genome Atlas (TCGA), which 
investigated a large PTC cohort by using a comprehensive multi-omics approach [6]. The study not 
only expanded the genomic landscape of PTC, but also proposed an improved molecular 
classification of PTC based on gene expression profiles that describe tumor properties better than 
pathological classifications [6]. The authors established a 71-gene signature, indicative of MAPK 
pathway transcriptional activation, that permits to classify BRAFV600E- and RAS-mutated PTCs and 
to determine whether a given tumor, characterized by other less common or unknown alterations, 
resembles one of these two molecular subtypes, defining a BRAF-like or RAS-like signaling type, 
respectively. The TCGA-based BRAF- or RAS-like signaling classification was then confirmed in 
subsequent studies not only in additional cohorts of PTC [7,8], FTC [8], PDTC, and ATC [5], but also 
in case lists including both tumoral and non tumoral thyroid tissues (reference [7] and our 
unpublished data). 
While collectively the definition of gene lesions and expression profiles have greatly expanded 
our understanding of the genetic basis of TC, the way cancer cells interact with the tumor 
microenvironment (TME) still represents a poorly investigated field in the context of thyroid cancer. 
Several lines of evidence have shown how tumor growth and progression can be affected by 
cellular (both of immune and not immune origin) and TME-related components [9]. Many genes 
encoding secreted factors with paracrine effects on TME components such as, for instance, stromal 
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cells (e.g., fibroblasts) and/or extracellular matrix proteins (e.g., collagen), have been found to be 
abnormally expressed in tumor tissues [9]. 
Recently Jolly et al. have described a mouse model driven by the thyroid-specific expression of 
oncogenic BRAFV600E where the converging action of thyroid tumor cells and stromal cancer-
associated fibroblasts (CAFs) promote TC progression [10]. According to the model, CAFs are 
recruited in the stroma at the tumor invasive front where they synthesize and deposit collagen 
(COL1A1), which is in turn cross-linked by the enzyme LOX, produced by thyroid tumor cells. 
Collectively, this coordinated action leads to matrix stiffness and progression from PTC to less 
differentiated PDTC. Interestingly, the authors reported this feature specifically in murine thyroid 
tumors driven by BRAFV600E mutation, but not in those driven by HRAS mutation. As validation of 
the proposed model, they investigated the expression of LOX and COL1A1 genes in human TC by 
using two public datasets [6,11] and confirmed their upregulation in thyroid tumors as well as the 
association with BRAF mutation, but not RAS mutation. The concurrent involvement and expression 
of CAF markers in human TC, however, remained unexplored. 
Another contribution in understanding the process of thyroid tumor progression, specifically in 
BRAFV600E mutated PTCs, has been recently provided by Kim et al. who reported the active 
involvement of senescent thyroid cancer cells (senescent TC cells) in the invasion and metastases of 
PTC [12]. Cellular senescence is a feature of steady status cell cycle arrest that can be induced by a 
variety of stress stimuli, including oncogene activation [12]. In this specific case, it is defined as 
oncogene induced senescence (OIS). The occurrence of OIS in thyroid has been already described in 
reference [13], as well as by our laboratory [14,15]. Along with cell cycle arrest, confirmed by 
increased expression of cell cycle inhibitors as p16INK4a and p21CIP1, another feature of senescent cells 
is to be metabolically active, secreting a myriad of growth factors, cytokines, and chemokines 
collectively termed SASP (senescence-associated secretory phenotype). The nature and composition 
of SASP varies depending on cellular context and can display pro- or anti-tumoral properties [16]. 
Kim et al. starting from the observation that senescent thyroid cells were frequently detected at the 
invasive front of human BRAFV600E-expressing PTCs, determined through subsequent in vitro and 
in vivo studies that these cells constitute a subpopulation of the thyroid tumoral cells and secrete 
factors that are able to stimulate the collective migration and invasion of the surrounding TC cells, 
thus promoting tumor invasiveness. Whether senescent TC cells secretome was able to affect 
additional players in TME was not explored. 
In this study, we exploited a retrospective case list of human thyroid tissues collected at our 
Institution, and included various tumor histotypes as well as paired and non-paired non-neoplatic 
thyroid (NT) controls, to investigate through immunohistochemical (IHC) and gene expression 
analyses whether the cross-talk between thyroid tumor cells and CAFs described in Jolly et al.’s 
mouse model also occurs in human TC, and whether senescent thyroid cells may be potentially 
involved in this process. 
In addition, we exploited tumor genetic characterization, both at molecular and transcriptomic 
levels, to correlate the results with the tumor genotype. An additional cohort of 407 human thyroid 
tissues was derived from public gene expression studies and tested as a validation set. 
2. Results 
2.1. CAFs Are Enriched at the Invasive front of Human Thyroid Cancers 
The presence of CAFs was investigated by using immunostaining with alpha-smooth muscle 
actin (α-SMA) in a series of 65 formalin-fixed paraffin-embedded (FFPE) tissue sections including 
thyroid tumors (of different histotypes, details are provided in Table S1) and NTs derived from 48 
patients (43 TC patients and 5 NT controls). For 32 FFPE tumor sections with available adjacent NT, 
the paired non tumoral thyroid was also scored. 
We found α-SMA positive areas, indicative of an activated fibroblasts presence, in human 
thyroid tumors (Figure 1A). In particular α-SMA positive areas localized preferentially in the stroma 
along the tumor invasive front, organized in peripheral structures as fibrotic capsule or septa that 
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were absent in the tumor center and NTs, where α-SMA staining was restricted to blood vessels 
(Figure 1A, magnification). The extent of stromal α-SMA positive areas, however, was quite 
heterogeneous ranging from very thick to absent (Figure 1A, α-SMA positive areas in the invasive 
front ranged from 0.2% to 28%, scored by digital quantification). We therefore wanted to test whether 
different CAF levels could be associated with specific tumor histotypes (See PTC, PDTC, and ATC in 
Figure S1). However we did not observe a clear stratification according to this parameter. 
 
Figure 1. Cancer-associated fibroblasts (CAFs) assessment by α-SMA immunohistochemical staining 
in human thyroid cancers. (A) A boxplot with a scatterplot showing IHC results expressed as α-SMA 
positive areas calculated by image digital quantification on the stained tissues section from non-
neoplastic thyroids (NT) and thyroid tumors (scored separately for invasive front (IF) and tumor 
center (TC)). Each dot represents the mean of 2–3 fields scored for each sample. Below an example of 
α-SMA stained tissue section (scale bar: 5 mm) with representative scored regions (high 
magnification, scale bar: 500 μm) and the corresponding ImageJ threshold mask with the measured 
positive area (expressed as a percentage). (B) Tumor genotyping results. Pie charts represent the 
distribution of identified driving lesions or BRAF-/RAS-like signaling in tumor tissues; wt: samples 
with no alterations in the tested lesions. (C) Boxplot with scatterplot showing α-SMA IHC results in 
tumor samples stratified for genetic driving lesion or BRAF-/RAS-like signaling. *** p-value < 0.0001 
and * p-value < 0.05 by Mann-Whitney test.  
Since Jolly et al. [10] reported specific fibroblasts recruitment in murine BRAFV600E TCs, we 
then assessed whether the heterogeneous CAF level could be associated with specific driving lesions, 
and in particular with BRAFV600E, rather than with a tumor histotype. 
Some of the tumor tissues reported in this study had been already characterized for driving 
lesions such as BRAFV600E and H/N/KRAS mutations, as well as RET and TRK gene fusions [17]. 
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Tumor genotyping for the same oncogenes was therefore completed for all the samples (Figure 1B 
and Table S1). Collectively, 42 out of 43 TC patients were screened for genetic alterations. A high 
fraction (60%) of these had positive results for the tested lesions, with BRAFV600E as the most 
frequently identified alteration. In addition, for a subset of tumors with unidentified lesions (40%, 
indicated as wild type (wt)), we could exploit gene profiles established on patient matched frozen 
tissue to investigate their oncogenic signaling. To achieve this aim, we applied the TCGA derived 71-
gene signature for BRAF-/RAS-like signaling classification [6] (Figure S2). Accordingly, we confirmed 
BRAF- and RAS-like signaling in BRAFV600E and RAS mutated samples, respectively, and obtained 
signaling information for 70% (12 out of 17) of wt tumors (those with available gene profiles, Table 
S1), decreasing to 12% of tumors with unidentified lesion or signaling (Figure 1B). 
In tumor samples stratified for gene drivers or signaling (Figure 1C), we found not only a higher 
level of α-SMA staining in BRAFV600E- compared with RAS-mutated tumors, but also in BRAF-like 
tumors compared with RAS-like tumors. 
Overall, we confirmed that CAFs are enriched at the invasive front of human thyroid cancers 
and in particular in those harboring BRAFV600E mutation or BRAF-like signaling. 
2.2. CAFs, COL1A1, and LOX Coordinated Expression in Human Thyroid Cancers 
We then investigated our tissue series for COL1A and LOX expression, and their possible 
association with CAFs and BRAF mutation or signaling. 
We found higher levels of COL1A1 and LOX in tumor tissues compared with NTs (Figure S3A), 
which resulted in more significant paired tissues (Figure 2A). In the same samples, α-SMA gene 
(ACTA2) was also highly expressed in tumors, confirming the presence of IHC staining. Focusing on 
tumor samples, we did not observe a clear stratification according to the tumor histotype (Figure 
S3B), even though high LOX and COL1A1 levels were detected in ATCs. In tumors stratified for gene 
drivers or signaling (Figure 2B), we found significantly higher levels of ACTA2, COL1A1, and LOX 
genes in BRAFV600E or BRAF-like tumors compared with RAS mutated or RAS-like tumors. 
 
Figure 2. α-SMA, COL1A1, and LOX gene expression in human thyroid cancers. (A) Boxplot with a 
scatterplot showing mRNA expression of α-SMA (ACTA2 gene), COL1A1, and LOX genes using 
quantitative RT-PCR in paired non-neoplastic thyroids (NT) and thyroid tumors. (B) The same genes 
displayed in tumor samples stratified for driving lesion or BRAF-/RAS-like signaling. qRT-PCR data 
are shown as a relative quantity normalized to the HPRT gene used as endogenous control for RNA 
input normalization. Each dot represents the mean of three technical replicates. * p-value < 0.05 using 
a Wilcoxon. matched test for pairs NT/tumor or the Mann-Whitney test. 
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Immunostaining on tissue serial sections (Figure 3) confirmed the coordinated expression of α-
SMA, COL1A1, and LOX. COL1A1 localized in tumor stroma and was closely correlated with α-SMA 
positive CAFs, whereas LOX was expressed by thyroid tumor cells. In addition, we observed the 
presence of tumor clusters organized as islands or chords detached from the main tumor mass and 
infiltrating the connective stroma (Figure 3, higher magnification). This feature of cancer cells of 
invading as cohesive groups, generally indicated as ‘collective invasion’, was preferentially detected 
in BRAFV600E tumors. 
 
Figure 3. α-SMA, LOX, and COL1A1 immunostaining in human thyroid cancers. Representative 
thyroid tumors serial sections from two different patients stained by IHC for α-SMA, COL1A1, and 
LOX protein expression and localization. In the top panel, the tumor edge/ invasive front is 
specifically shown (scale bar 500 μm), while lower panel has higher magnification (scale bar 200 μm). 
* clusters of tumor invading cells detaching from the principal tumor mass (T). 
Overall, we showed the concurrent expression of α-SMA, LOX, and COL1A1 genes and proteins 
in BRAF-driven human thyroid tumors, where we also detected stroma associated local invasion. 
2.3. Senescent Thyrocytes Are Present at the Invasive front of Thyroid Cancers and Closely Related to CAFs 
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As Kim et al. [12] described a similar mechanism of invasion mediated by senescent TC cells in 
BRAFV600E mutated PTCs, we wanted to test whether senescent thyrocytes could be detected at the 
α-SMA positive and collagen rich stroma interface. 
We examined the expression of p16, a recognized marker for the study of OIS and senescence in 
vivo. We found higher levels of the p16 gene in tumor tissues compared to NT, where it was barely 
detectable (Figure 4A). In tumors stratified for gene drivers or signaling (Figure 4B), we found a trend 
toward p16 higher expression in BRAF-driven (BRAFV600E or BRAF-like) tumors compared with 
RAS-driven (RAS mutated or RAS-like) tumors, even though this trend was not statistically 
significant. 
 
Figure 4. Senescent thyrocytes and CAFs assessment in human thyroid cancers. (A) Boxplot with a 
scatterplot of p16 mRNA expression by qRT-PCR in non-neoplastic thyroids (NT) and thyroid tumors 
and (B) in tumor samples stratified for driving lesion or BRAF-/RAS-like signaling. qRT-PCR data are 
shown as a relative quantity normalized to the HPRT gene used as an endogenous control. Each dot 
represents the mean of three technical replicates. (C) Representative serial sections of a BRAFV600E 
mutated thyroid tumor IHC stained with p16 and α-SMA (senescent cells and CAFs markers, 
respectively). Scale bar: 100 μm. (D) Correlation between α-SMA positive areas and p16 positive cells 
established by IHC. (E) Boxplot with a scatterplot of p16 IHC staining results in tumors stratified for 
driving lesions or signaling. 
We then performed p16 immunostaining on tissue serial sections adjacent to those assessed for 
α-SMA immunostaining (Figure 4C). We found p16 positive cells in tumor tissues, in agreement with 
our previous published results [14,15] and localized preferentially at the tumor invasive front 
(Figures 4C and S4), in agreement with Kim et al. [12]. p16 positive cells were confirmed to be thyroid 
tumor cells through a morphological assessment and the expression of BRAFV600E (assessed by the 
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BRAFV600E-specific monoclonal antibody) and TTF-1 (the thyroid specific transcription factor-1) 
(Figures 4C and S4). Cellular senescence was further confirmed by the expression of additional 
markers, including p21 and Ki67 (cell proliferation marker) (Figure S4). The p21 expression pattern 
was similar to p16 in localizing at the tumor invasive front, even though less intense staining was 
observed, and the absence of proliferative activity was further confirmed by the lack of Ki67 
expression in p16 and p21 positive cells. Of note, we found that p16 positive cells were closely related 
(Figure 4C) and significantly correlated with CAFs (α-SMA positive stromal areas, see Figure 4D). 
Higher levels of p16 positive cells were recorded, in agreement with α-SMA expression (Figure 2B) 
and IHC staining (Figure 1C), in BRAFV600E or BRAF-like tumors compared with in RAS mutated 
tumors (Figure 4E). 
Overall, we confirmed the co-occurrence of senescent thyroid cells and CAFs at the invasive 
front of BRAF-driven human thyroid cancers. 
2.4. Concurrent Upregulation of LOX, COL1A1, CAFs and Senescent Cells Markers in Thyroid Cancer 
Gene Profiles 
Solid tumors consist of both tumor cells and TME, including stromal cells. As a consequence, 
gene profiles obtained from such complex tissues are a mixture of RNA transcripts derived from all 
of these components. We wanted to assess the concurrent expression of genes detected in both 
tumoral (LOX and p16) and stromal compartments (α-SMA and COL1A1). We exploited the 
transcriptomic profiles available for a subset of tissues of our series (Table S1) and investigated the 
expression of α-SMA, COL1A1, LOX, and p16 genes. We included the FAP gene (fibroblast activation 
protein, a well known activator of CAFs specifically expressed by stroma [18]) as an additional 
marker for CAFs (Figure 5). In line with the so far described results, we confirmed the concurrent 
high expression of both tumoral and stromal derived genes in tumor tissues and in particular in those 
characterized by BRAF-like signaling (11 out of 17 BRAF-like tumors clustered in the 5-genes 
overexpressing group; p-value 0.0032). 
 
Figure 5. Unsupervised hierarchical clustering analysis of proprietary gene dataset on 5 tumoral and 
stromal genes. The color scale bar represents the relative gene expression levels normalized by the 
standard deviation. Color legend for tissue and BRAF-like/RAS-like signaling is reported. α-SMA and 
p16 are indicated by the corresponding gene symbol, ACTA2 and CDKN2A, respectively. 
To further confirm this co-occurrence, we interrogated additional thyroid tissue gene datasets 
that are publicly available on the GEO repository. 
Ten gene sets were selected (details in Figure 6A). Taking advantage of the fact that all sets were 
profiled by the same microarray platform, we could analyze the samples as a unique series of 407 
thyroid tissues, including 254 TCs of different histotypes, 146 paired NTs, and seven unpaired NT 
controls. Since detailed information about driving lesion were available only for a fraction of tumors 
(113 out of 254 TCs, 44%; Table S2), we exploited the TCGA-derived 71 gene signature [6] to infer 
their BRAF- or RAS-like signaling (Figure S5). By using this approach, we not only confirmed BRAF-
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/RAS-like signaling in samples with identified drivers, but also obtained signaling information in 
tumors with unknown or not available lesions (69/254 (27%) and 72/254 (29%), respectively; see Table 
S2). Of note, in agreement with a previous report [7], we found in the GEO derived sample series 
(Figure S5), as well as in our proprietary series (Figure S2), that non-neoplastic thyroids display RAS-
like signaling, suggesting how this feature could be not exclusively associated to oncogenic RAS but 
rather to MAPK pathway reduced activation that is also observed in normal thyroid follicular cells. 
Unsupervised clustering confirmed the target genes (LOX, p16, α-SMA, COL1A1, and FAP) 
upregulation in thyroid cancers and in particular in those with BRAF-like signaling (115 out of 206 
BRAF-like tumors clustered in the 5-genes overexpressing group; p-value < 0.0001) (Figure 6B). 
 
 
Figure 6. Assessment of tumoral and stromal derived genes in human thyroid cancers gene sets 
derived from Gene Expression Omnibus (GEO). (A) Gene sets description. (B) Unsupervised 
hierarchical clustering analysis of 407 samples derived from GEO datasets on five tumoral and 
stromal genes. The color scale bar represents the relative gene expression level normalized by the 
standard deviation. Color legend for the tissue, BRAF-like/RAS-like signaling, and CAF score is 
reported. α-SMA and p16 are indicated by the corresponding gene symbol, ACTA2 and CDKN2A, 
respectively. 
In addition, recently Isella et al. [19] have described gene signatures that are useful for assessing 
the contribution of stromal components, including CAFs, in tissue transcriptional profiles. In 
particular they reported a 131 genes signature, specifically expressed by CAFs, that can be exploited 
to calculate a CAF score indicative of the presence of stromal CAF. Based on this gene signature, we 
calculated the CAF score in the same GEO derived series and verified that the fraction of BRAF-like 
tumors displaying upregulation of LOX, COL1A, CAFs, and senescent cells markers is concurrently 
enriched for a high CAF score (Figure 6B). 
Overall, these results confirm the concurrent gene upregulation of LOX, COL1A1, senescent 
cells, and CAFs markers in tumor tissues and in particular in those with BRAF-like signaling. 
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3. Discussion 
Previous reports have separately investigated the functional role of cancer-associated fibroblasts 
[10] and senescent TC cells [12] in the progression of BRAFV600E driven PTC. In this study, we 
exploited a combined approach of immunohistochemistry and gene expression analyses, coupled 
with tumor genotyping, to simultaneously investigate the occurrence of these two cell types in a 
proprietary series of human thyroid cancers, as well as in multiple public gene expression datasets. 
We found stromal CAF recruitment at the tumor invasive front associated with collagen 
deposition and LOX expression by the adjacent thyroid tumor cells. In addition, we detected clusters 
of invading tumor cells at the CAFs and collagen rich tumor-stroma interface where senescent TC 
cells were also identified, displaying significant co-occurrence with CAFs. 
While the cross-talk of CAFs-TC cells has been already confirmed in functional analyses [10] and 
here in human tissues, how CAFs are recruited and/or activated in the tumor stroma remains to be 
established. In this scenario, senescent cells represent an attractive candidate for their ability of 
affecting surrounding cells and TME by the secretion of multiple factors (SASP). Our results, 
describing the co-occurrence of CAFs and senescent TC cells at the tumor-stroma interface, are in line 
with this hypothesis and suggest senescent TC cells as a possible source of secreted factors involved 
in the recruitment and/or activation of stromal fibroblasts. In turn CAFs, through a concerted action 
with thyroid tumor cells, lead to extracellular matrix stiffness through the deposition and LOX 
mediated cross-linking of collagen fibers, as shown by Jolly et al. and here confirmed in human 
tissues. In addition, our results show how the collagen-rich stroma appears to draw a privileged route 
by which clusters of tumor cells could migrate detaching from the main tumor mass as a first step 
toward local invasion. 
While Kim et al. demonstrated the role of senescent TC cells in the invasive phase, where they 
lead TC cells migration [12], their possible early role on CAF recruitment/activation, as well as the 
secreted mediators involved, remain to be verified and future functional studies will be conducted to 
investigate this issue. To the best of our knowledge, no studies about senescent TC cells and CAFs 
are currently available. Some studies have assessed the interactions between senescent cells and other 
cell types as platelets [20] and immune cells [21]. In addition, our laboratory has recently described 
an interplay between senescent thyrocytes and macrophages [22]. Several works (reviewed in 
reference [16]) describe the presence of senescent fibroblasts along with CAFs in tumor stroma and 
how both can promote tumor aggressive features. In our IHC analyses, we only identified few 
patients harboring senescent fibroblasts, while senescence was detected in tumor cells in the vast 
majority of patients, suggesting that the cellular type undergoing to cellular senescence could vary 
based on the specific tumor context. 
However, some evidence suggests that there is a possible cross-talk between senescent cells and 
CAFs. It is known that tumor cells release paracrine factors able to attract and/or activate CAFs [16]; 
for instance, transforming growth factor (TGF)-β1 [23], interleukin (IL)-1, and IL-6 [24] have been 
reported in the activation of fibroblasts. Accordingly, tumor cells expressing TGF-β1 have been 
associated with α-SMA fibroblasts in PTC [25]. Interesting, these factors were also identified in 
senescent thyroid cells. TGF-β1 [22], IL-1, and IL-6 [12,15,22] are expressed by two thyroid models of 
oncogene-induced senescence, as well as by senescent TC cells at the invasive border of human PTCs 
[12]. It is noteworthy that we found that the same mediators (TGF-β1, IL-1 and IL-6) are expressed by 
tumors with high LOX, collagen, CAFs, and senescent cells markers (Figure S6), supporting the 
hypothesis of a possible cross-talk between CAFs and senescent TC cells. In line with CAF activation 
mediated by thyroid tumor cells, Jolly et al. [10] reported that BRAFV600E TC cells, derived from 
their mouse model, secrete factors that are able to promote the proliferation and migration of two 
CAF cell lines. Jolly et al. did not assess whether part of these tumor cells expressed senescence 
markers, but it is interesting that the secretome of HRAS-mutated thyroid tumors cells did not cause 
these stimulatory effects, consistently with our findings that CAFs and senescence markers do not 
often co-occur in RAS-driven human thyroid tumors. 
In addition to PTC, we investigated CAFs in aggressive forms as PDTC and ATC. However, we 
did not see a clear correlation with specific histotypes (Figure S1), but instead we found an association 
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with tumor genotype showing higher levels of CAFs in BRAF-driven tumors (Figure S7A). This 
finding could be interpreted in light of the notion that some genetic alterations (such as BRAFV600E 
and RAS mutations) even though specific, or at least more frequent, in certain TC histotypes 
(papillary versus follicular) are commonly shared among well differentiated and poorly or 
undifferentiated forms. As PDTC and ATC may arise from both PTC and FTC, they also can be 
driven, as their corresponding WDTC of origin, by BRAF/MAPK or RAS/PI3K-AKT pathway 
alterations, thus displaying genotypic and phenotypic differences. This was also confirmed in public 
GEO datasets (Figure 6), where tumors displaying high target genes levels are BRAF-driven PTCs 
and ATCs, while most of the PDTCs of the series, characterized by RAS-like signaling, downregulate 
the same genes. The proposed model in which CAFs-TC cells cross-talk promotes the progression 
from PTC to aggressive PDTC [10] thus requires a specification: this interaction is accordingly 
observed in human thyroid tumors, both in PTC and aggressive PDTC or ATC, but it appears to be 
distinctive for BRAF-driven tumors. In line with the idea of a linear progression from less to more 
advanced forms, we found increased expression of α-SMA, COL1A1, and LOX in the more aggressive 
tumor component (ATC versus PTC or PTC tall cell versus a classical variant) in two TC patients of 
our series for whom a tumor with a mixed component or multiple tumor specimens were available 
(Figure S7B). This finding, however, needs to be verified in additional and large case lists possibly 
comprising patient matched tumor tissues with various degrees of aggressiveness. 
Our results suggest the possibility that CAFs and TC cells may interact to promote tumor local 
invasion. Only a few previous studies have investigated CAFs in human thyroid tumors and were 
mainly focused on PTC, in which the occurrence of CAFs has been accordingly reported in tumor 
stroma [25–29] and associated with aggressive features as advanced stage [25] and lymph node 
metastases (LNMs) [26;28]. The presence of fibrotic collagenous stroma has been significantly 
associated with LNMs and peritumoral invasion in papillary thyroid microcarcinomas [30]. In 
addition, increased expression of CAF-related proteins was significantly found in stromal cells of 
classical compared to the follicular variant of PTC and in BRAFV600E mutated PTCs, where a tumor 
infiltrative margin was also detected [27]. 
Interestingly, Kim et al. [12] reported that senescent TC cells can promote not only local invasion, 
but also LNMs, identified in more than half (61%) of the investigated BRAFV600E PTC patients. The 
correlation between BRAF mutation and aggressive features, including LNMs, has been already 
described not only in PTC, but also in aggressive forms. Landa et al. [5] reported that BRAF-mutant 
PDTCs had a higher frequency of nodal metastases than RAS-mutant PDTCs that, instead, displayed 
a higher rate of distant metastases.  
This appears to be in line with an idea of genotype-phenotype correlation: alterations involving 
BRAF or other genes that activate the MAPK pathway (for instance, several RET gene fusions 
reported in reference [6] and here confirmed displaying BRAF-like signaling -see Tables S1 and S2-) 
are more frequently detected in TCs of papillary origin (PTC and PDTC/ATC that derive from PTC) 
that display more frequent metastatic spreading through lymphatic vessels and LNMs. Meanwhile, 
alterations involving RAS or other genes (PAX8/PPARG, specific gene fusions and PI3K pathway 
effectors) that display RAS-like signaling are more frequently detected in TCs of follicular origin (FTC 
and PDTC/ATC that derive from FTC) that display more frequent spreading via blood vessels and 
distance metastases. 
It is conceivable, therefore, to speculate that the TC invasiveness, observed here in the presence 
of both CAFs and senescent cells, could be not limited to local invasion but possibly could also 
expand to LN dissemination, in line with Kim et al.’s model [12]. To test this hypothesis, we assessed 
whether tumors with high LOX, collagen, CAFs, and senescent cells markers could also be associated 
with lymph node metastases. In our series, we consistently found that nine out of 12 tumors with 
high expression of the target genes (Figure 5) had LNMs. For the remaining three tumors, an LN 
assessment and status was not available (Table S1, NX). In the series derived from GEO, this analysis 
was not applicable as records about LNs were limited. We, therefore, assessed the series of PTCs 
derived from TCGA [6] (available on www.cbioportal.org with complete clinicopathological records) 
and confirmed that PTCs with coordinated high expression of the tested genes (LOX, COL1A1, p16, 
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ACTA2 and FAP) were also significantly associated with LNMs (Figure S8), in agreement with our 
hypothesis. 
Even though additional functional studies are required to address some open questions, we 
believe that the present study, showing how CAFs and senescent TC cells are both present at the 
tumor invasive front of BRAF-driven TCs, highlights that they represent additional players worthy 
of being studied for a better understanding of the metastatic process in TC. 
4. Materials and Methods 
4.1. Tissue Samples Collection and Nucleic Acid Extraction 
A retrospective series of non-consecutive human thyroid tumors including PTCs, PDTCs, and 
ATCs was investigated in the present study, and clinicopathological features are summarized in 
Table S1. Tumor tissues were collected from patients diagnosed with thyroid carcinoma and 
undergoing surgical resection. Whether paired non-neoplastic thyroid tissue was available from the 
same patient, it was also investigated. Additional normal thyroid controls from patients with 
pathologies other than thyroid cancer were included. Tissue samples were obtained from the 
Department of Pathology at Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (INT). The 
study was approved by the Independent Ethics Committee of INT (code number INT 55/14). 
Formalin-fixed paraffin-embedded (FFPE) tissue blocks were cut in serial sections and processed for 
histological review, DNA and RNA extraction, and immunohistochemistry (IHC). Histological 
review was performed by expert pathologists on hematoxylin and eosin (H&E) stained sections and 
tumor tissues were classified according to WHO Classifications [31] and using the pathological 
tumor-node-metastasis (pTNM) staging system [32]. 
DNA was extracted from FFPE tumor tissues. Methylene blue-stained sections (7 μm) were 
microdissected to select tumoral and non tumoral tissues, while all tumoral sections contained at least 
80% of a neoplastic component. Tumor genomic DNA was extracted using the Qiamp FFPE DNA kit 
(Qiagen, Hilden, Germany) and was used for tumor genotyping. 
RNA was extracted from manually macrodissected unstained sections (5 μm) using adjacent 
H&E slides as a guide for whether matched NT tissue was available from the same section and could 
be extracted as a separate sample. RNA was extracted by miRNeasy FFPE kit (Qiagen) and used for 
gene fusion detection in tumor genotyping and for qRT-PCR analyses. 
A subset of patients, based on frozen tissue availability, were further investigated by gene 
expression profiling. H&E stained sections from snap-frozen tumoral samples were reviewed by an 
expert pathologist for tissue representativeness control and were subjected to RNA extraction (see 
section 4.5). 
4.2. Tumor Tissue Genotyping 
Tumor samples were screened for some of the most common thyroid oncogenes, including 
BRAF and N/H/KRAS mutations as well as RET and TRK gene fusions. BRAF (exon 15), N/HRAS 
(exon 2), and KRAS (exon 2 and 3) mutational analysis was performed on tumor genomic DNA by 
using PCR specific primers that were previously described [33,34]. PCR products were then subjected 
to direct sequencing using 3500 DX Genetic Analyzer (Applied Biosystems, Thermo Fisher Scientific, 
Waltham, MA, USA) and evaluated by using ChromasPro software. Gene fusions analysis was 
performed on tumor RNA reverse transcribed in cDNA and assessed by RET and TRK specific 
primers as previously described [17]. Samples that were not mutated or rearranged for the tested 
genes were indicated as being of the wild type (wt). 
4.3. Immunohistochemistry 
IHC analyses were performed on FFPE tumor sections (2 μm) by means of an automated 
immunostaining device (Autostainer link48 Dako, Agilent, Santa Clara, CA, USA) using anti-human 
α-SMA (actin smooth muscle, clone 1A4, M085101-2, 1:800, Dako) and anti-TTF1 (#86763, 1:2000, 
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Dako). Immunostaining of COL1A1 (NB600-408, 1:400, Novus Biologicals, Centennial, CO, USA), p16 
(p16INK4a, prediluted, CINtec®, Roche, Basel, Switzerland), and BRAFV600E (06918727001, prediluted, 
Roche)was performed on Benchmark ULTRA IHC instrument (Ventana, Roche). LOX expression was 
assessed by using heat-induced epitope retrieval (pressure cooker) and immunostaining with anti-
LOX (NB100-2530 1:400, Novus Biologicals). 
The assessment of α-SMA immunostaining was performed by digital quantification using 
ImageJ software. For each tissue section representative images of different regions (tumor center, 
tumor invasive front and, whether available, adjacent non-neoplastic thyroid) were captured (Nikon 
ECLIPSE E600, Nikon Corporation, Tokyo, Japan), with two or three fields acquired per region. As 
α-SMA immunostains also contained blood vessels pericytes, to avoid quantification artifacts, fields 
were selected in areas with negative vascular structures or harboring, at least, very low vascularity 
(less than 3% of the scored field). Images were thresholded and processed by using the analyze-
measure tool in ImageJ setting as the output for the area fraction measurement (indicative of the 
stained areas percentage relative to the total field). 
The assessment of p16 immunostaining was determined as number of p16 positive tumor cells 
relative to the total tumor cells in the tissue slice expressed as a percentage. 
4.4. Quantitative Real-Time Reverse Transcription PCR (qRT-PCR) 
The expression of LOX, COL1A1, αSMA (ACTA2 gene), and p16 (CDKN2A gene) was determined 
by a two-step quantitative real-time PCR on RNA extracted from FFPE tissue slices. RNA was reverse 
transcribed by SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen, Thermo Fisher 
Scientific) and quantified by TaqMan Universal PCR Master Mix and Gene Expression Assays (LOX 
hs00942483_m1; COL1A1 hs01076773_g1; ACTA2 hs00909449_m1; CDKN2A hs99999189_m1) 
(Applied Biosystems, Thermo Fisher Scientific). HPRT gene (assay hs02800695_m1) was used as an 
endogenous control for data normalization. All qRT-PCRs were performed in triplicate on the ABI 
PRISM 7900HT Real-Time PCR System. Data were analyzed with SDS 2.4 and RQ Manager 1.2.1 
software (Applied Biosystems) using the 2−ΔΔCt method. 
4.5. Gene Expression Profiles-Proprietary Series 
RNA was extracted from snap-frozen tissues and quantified by NanoDrop ND-10 
Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) as previously described [17]. 
RNA quality was evaluated by the RNA Integrity Number (RIN) assessed using Agilent 2100 
Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA), since the obtained RNA was of a variable 
quality (mean RIN 4.9, range 1.8–7.8) gene profiles were established by HumanHT-12 WG-DASL V4.0 
R2 expression beadchip (Illumina, San Diego, CA, USA), and was optimized to ensure high 
performance from difficult or partially degraded RNA samples. RNA labeling, processing, and 
hybridization were performed according to Illumina standard protocols, and microarrays were 
scanned with a Illumina BeadArray Reader. Array data were obtained using Illumina BeadStudio 
v3.3.8 and processed using the lumi package [35]. Raw data were log2-transformed, normalized using 
robust spline normalization, and filtered keeping probes with a detection p-value < 0.01 in at least 
one sample. Probes were annotated to HUGO gene symbols using the 
illuminaHumanWGDASLv4.db package (Illumina). Multiple probes representing the same gene 
were collapsed using the collapseRows function of the WGCNA package [36] with the 
“maxRowVariance” method. All analyses were performed using R version 3.3.0 and Bioconductor 
[37] version 3.4. Microarray data were deposited and are available on NCBI Gene Expression 
Omnibus (GEO) database (www.ncbi.nlm.nih.gov/geo/) with the accession number GSE104005. Part 
of the expression profiles of this series has been already published [17]. 
The BRAF-/RAS-like signaling and LOX, COL1A1, αSMA (ACTA2 gene), p16 (CDKN2A gene), 
and FAP genes expression were investigated in this series as described below. 
4.6. Gene Expression Profiles-Public Datasets 
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Ten human thyroid cancer gene sets publicly available in the GEO repository (GSE3467 [38], 
GSE6004 [39], GSE33630 [40,41], GSE76039 [5] GSE35570 [42], GSE65144 [43], GSE53157 [44], 
GSE29265, GSE3678, and GSE60542 [45]) and profiled on the same microarray platform (Human 
Genome U133 Plus 2.0 Array, Affymetrix, Santa Clara, CA, USA) were used in the present study. For 
the GSE35570, series we excluded 65 samples as duplicated in GSE33630 from the same laboratory. 
For the GSE60542 series, we focused on primary PTCs and paired NTs. A single series of 407 unique 
cases was obtained, thus comprising 176 PTC, 52 ATC, 22 PDTC, and 4 FTC, together with 153 normal 
thyroid samples. Robust Multi-array Average (RMA) normalization [46], BrainArray annotation 
(http://brainarray.mbni.med.umich.edu/, version 20.0.0) [47] and batch correction by sva 
R/Bioconductor package [48] were applied to raw intensity values, as previously described [49]. 
In order to investigate the expression of LOX, COL1A1, αSMA (ACTA2 gene), p16 (CDKN2A 
gene), and FAP genes across the entire dataset, a hierarchical clustering approach was performed 
using the euclidean distance metric and centroid linkage method, by means of the DNAChip 
Analyzer [50]. 
4.7. BRAF-Like and RAS-Like Signaling 
The BRAF-/RAS-like signaling was investigated in 407 samples dataset by exploiting the TCGA-
derived 71 genes signature [6]. The corresponding BRAF- or RAS-like molecular group was attributed 
to each sample by using hierarchical clustering analysis (Pearson’s correlation metric and average 
linkage method) on the global 71-gene list expression pattern across the entire series (Figure S5). The 
same kind of analysis was performed on the proprietary dataset using 68 genes out of the 71-gene 
signatures available on Illumina array (Figure S2). 
4.8. CAF Score 
The CAF score was attributed to all 407 samples by using the 131 genes signature previously 
reported by Isella et al. [19]; of the 131 genes, 125 were available on HG-U133 Plus 2.0 array and were 
used to compute the CAF score. The 125 genes average expression value was calculated for each 
sample and the entire dataset was classified in CAF score quartiles and further in low (first to third 
quartile) or high (top quartile) CAF score level. 
4.9. Statistical Analysis 
Statistical analyses were performed using GraphPad Prism software (version 5.02, GraphPad 
Software, San Diego, CA, USA). Groups were compared using the non parametric Mann-Whitney 
test or Wilcoxon matched pairs test for tumor/non-neoplastic thyroid matched samples; p-values < 
0.05 were considered to be significant. Correlation was tested by the non parametric Spearman 
correlation coefficient (r). 
5. Conclusions 
The analyses on human thyroid cancer tissues presented in this work provide lines of evidence 
that not only confirm previous reports about the involvement of cancer-associated fibroblasts and 
senescent TC cells in BRAFV600E-expressing PTC, but also provide a revised and improved model 
of thyroid cancer invasion in which these two cell types may possibly cooperate to promote the 
invasiveness of other thyroid cancers driven by BRAF-associated oncogenic events. 
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